方盛制药(603998.SH)：公司通过药品GMP符合性检查

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a GMP compliance inspection notice from the Hunan Provincial Drug Administration, indicating that its production lines meet GMP requirements, which will help the company diversify its product offerings and maintain stable production capacity to meet market demand [1] Group 1 - The company received the GMP compliance inspection notice for its production facilities located in the Hunan Wangcheng Economic Development Zone [1] - The inspection covered the production lines for Ezetimibe and Benidipine in the raw material drug workshop [1] - The compliance with GMP standards is expected to enhance the company's ability to meet market needs and ensure stable production capabilities [1]